NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Read More
Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline.
Read More
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL).
Read More
